Literature DB >> 16284738

[Renal cancer study activities in Germany. Drug therapy].

D Rohde1.   

Abstract

Drug therapy of advanced renal cell carcinoma underwent rapid changes. Monotherapeutic, placebo-controlled protocols -- and more recently combinations of different targeted drugs -- dominated the global clinical studies in the past 2 years. The preliminary results are almost encouraging and international investigators, supported by the pharmaceutical industry, were most successful in enrolling patients quickly. The present article reviews the recent German drug study activities and indicates potential future projects.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16284738     DOI： 10.1007/s00120-005-0943-0

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  7 in total

1.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

Authors:  S Negrier; B Escudier; C Lasset; J Y Douillard; J Savary; C Chevreau; A Ravaud; A Mercatello; J Peny; M Mousseau; T Philip; T Tursz
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

Review 2.  Immunotherapy for advanced renal cell cancer.

Authors:  C Coppin; F Porzsolt; A Awa; J Kumpf; A Coldman; T Wilt
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

3.  A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.

Authors:  Nancy A Dawson; Chuanfo Guo; Richard Zak; Brenda Dorsey; Jeanne Smoot; Jade Wong; Arif Hussain
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

4.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

5.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Authors:  J Atzpodien; H Kirchner; U Jonas; L Bergmann; H Schott; H Heynemann; P Fornara; S A Loening; J Roigas; S C Müller; H Bodenstein; S Pomer; B Metzner; U Rebmann; R Oberneder; M Siebels; T Wandert; T Puchberger; M Reitz
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

6.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.

Authors:  Dieter Jocham; Axel Richter; Lothar Hoffmann; Klaus Iwig; Dirk Fahlenkamp; Günther Zakrzewski; Eberhard Schmitt; Thomas Dannenberg; Walter Lehmacher; Jörn von Wietersheim; Christian Doehn
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

7.  Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Authors:  J Atzpodien; E Schmitt; U Gertenbach; P Fornara; H Heynemann; A Maskow; M Ecke; H H Wöltjen; H Jentsch; W Wieland; T Wandert; M Reitz
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640
  7 in total
  1 in total

1.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.